Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Chief Clinical Dev. Officer | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.97 · Expires 2031-09-01 | Direct | 23,325 |
Reported balance
After 2021-09-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-02 · Grant · Acquired 23,325 · Balance 23,325 F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 3,888 |
Reported balance
After 2021-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-02 · Grant · Acquired 3,888 · Balance 3,888 F2: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
F2: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
F3: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2021 Filed Sep 7, 2021 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008655 · edgar.xml · derivative · entry 2 Pano Arian · CIK 0001867891 · Chief Clinical Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,888 Underlying: Class A Common Shares · 3,888 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 23,325 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001179110-21-008655 · edgar.xml · derivative · entry 1 Pano Arian · CIK 0001867891 · Chief Clinical Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,325 Underlying: Class A Common Shares · 23,325 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.